Non-alcoholic hepatic steatosis: An update;Esteatosis hepática no alcohólica. Puesta al día

Atencion Primaria

Volumn 40, Issue 8, 2008, Pages 419-424

  Caballería Rovira, Llorenç ^a,b   Torán Montserrat, Pere ^b   Auladell Llorens, María Antonia ^a,b   Pera Blanco, Guillem ^b  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b IDIAP Jordi Gol ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; BETAINE; CLOFIBRATE; GEMFIBROZIL; LOSARTAN; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PRAVASTATIN; PROBUCOL; ROSIGLITAZONE; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DYSLIPIDEMIA; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; RISK FACTOR; ALGORITHM; FATTY LIVER; HUMAN;

ALGORITHMS; FATTY LIVER; HUMANS;

EID: 59449101998     PISSN: 02126567     EISSN: 15781275     Source Type: Journal    
DOI: 10.1157/13125408     Document Type: Article

References (36)

1. Ludwig J., Viggiano T.R., McGuill D.B., and Ott B.G.J. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hither to unnamed disease. Mayo Clinic Proc 55 (1980) 434-438
2. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., and Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study. Hepatology 42 (2005) 44-52
3. Bellentani S., Tiribelli C., Sacciccio G., Sodde M., Fratti M., De Martin C., et al., and the Dionysos Study Group. Prevalence of chronic liver disease in the general population of Northern Italy: The Dionysos Study. Hepatology 20 (1994) 1442-1449
4. Bellentani S., Saccoccio G., Masutti F., Crocè L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
5. Parés A., Tresserras R., Núñez I., Cerralbo M., Plana P., Pujol F.J., et al. Prevalencia y factores asociados a la presencia de esteatosis hepatica en varones adultos aparentemente sanos. Med Clin (Barc) 114 (2000) 561-565
6. Lee J.Y., Kim K.M., Lee S.G., Yu E., Lim Y.S., Lee H.C., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. J Hepatol 47 (2007) 239-244
7. Reid A.R. Nonalcoholic steatohepatitis. Gastroenterology 121 (2001) 710-723
8. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1331
10. Caballería J., and Rodés J. Esteatohepatitis no alcohólica. Med Clin (Barc) 120 (2003) 670-675
11. Pagano C., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., et al., Non-alcoholic steatohepatitis, insulin resistance and metabolic syndrome. Further evidence for an etiologic association. Hepatology 35 (2002) 367-372
12. Day C.P., and James O.F.W. Steatohepatitis: a tale of two «hits»?. Gastroenterology 114 (1998) 842-844
13. Adams L.A., and Talwalkar J.A. Diagnostic evaluation of non-alcoholic fatty liver disease. J Clin Gastroenterol 40 (2006) S34-S38
14. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 1705-1725
15. Mottin C.C., Moretto M., Padoin A.V., Swarowsky A.M., Toneto M.G., Glock L., et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 14 (2004) 635-637
16. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al., Nonalcoholic Steatohepatitis Clinical Research Network. Desing and validation of a histologic scoring system for NAFLD. Hepatology 41 (2005) 1313-1321
17. Mofrad P., Contos M.J., Haque M., Sargeant C., Fisher R.A., Luketic V.A., et al. Clinical and histological spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003) 1286-1292
18. Sakugawa H., Nakayoshi T., Kobashigawa K., Yamashiro T., Mashiro T., Miyagi S., et al. Clinical uselfulness of biochemical markers of liver fibrosis in patients with NAFLD. World J Gastroenterol 11 (2005) 255-259
19. Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonihay L., et al., LIDO study group, CYTOL study group. Diag-nostic value of biochemical markers (Fibro Test-Fibro Sure) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6 (2006) 6
20. Poynard T., Ratziu V., Charlotte F., Messous D., Munteanu M., Imbert-Bismut F., et al., LIDO study group, CYTOL study group. Diagnostic value of biochemical markers (Nash Test) for the prediction of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6 (2006) 34
21. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: a non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007) 846-854
22. Ziol M., Handra-Luca A., Kettaneh A., Christidis C., Mal F., Kazemi F., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 (2005) 48-54
23. De Ledinghen V., Beaugrand M., Kelleher T.B., Foucher J., Castera L., Ziol M., et al. Prediction of liver fibrosis in non-alcoholic steatohepatitis (NASH): risk factors and diagnostic potential of liver elasticity using Fibroscan. J Hepatol 44 Suppl 2 (2006) S39
24. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
25. Suzuki A., Lindor K., St Saver J., Lymp J., Mendes F., Muto A., et al. Effect of changes on body weight and lifestyle in NAFLD. J Hepatol 436 (2005) 1060-1066
26. Moreno Sánchez D. Tratamiento médico de la hepatopatía grasa no alcohólica primaria. Med Clin (Barc) 125 (2005) 108-116
27. Zelber-Sagi S., Kessler A., and Brazowsky E. A double-blind randomised placebo-controlled trial of orlistat for the treatment of NAFLD. Clin Gastroenterol Hepatol 4 (2006) 639-644
28. Sabuncu T., Nazligui Y., Karaoglanoulu M., Ucar E., and Kilic F.B. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with NASH. Rom J Gastroenterol 12 (2003) 189-192
29. Mathurin P., Gonzalez F., Kerdraon O., Leteurtre E., Arnalsteen L., Hollebecque A., et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 130 (2006) 1617-1624
30. Nair S., Diehl A.M., Wiseman M., Farr Jr. G.H., and Perrillo R.P. Metformin in the treatment of NASH: a pilot open label study. Aliment Pharmacol Ther 20 (2004) 23-28
31. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., et al. A randomized controlled trial of metformin vs vitamin E or prescriptive diet in NAFLD. Am J Gastroenterol 100 (2005) 1082-1090
32. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. Hepatology 39 (2004) 188-196
33. Sanyal A.J., Mofrad P.S., and Contos M.J. A pilot study of vitamin E vs vitamin E and pioglitazone for the treatment of NASH. J Clin Gastroenterol Hepatol 2 (2004) 1107-1115
34. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 41 (2005) 690-695
35. Ekstedt M., Franzen L.E., Mathiesen U.L., Holmqvist M., Bodemar G., and Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated enzymes: A histopathological follow-up study. J Hepatol 47 (2007) 135-141
36. Merat S., Malekzadeh R., Sohrabi M.R., Sotoudeh M., Rakhshani N., Sohrabpour A.A., et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomised controlled trial. J Hepatol 38 (2003) 414-418